An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.
Advanced Solid Tumor|Lymphoma
DRUG: ALPN-202
Adverse Events, Type, incidence, and severity of adverse events as assessed by CTCAE, Up to 30 days after last dose of study drug
Objective response, Best observed objective responses as assessed by RECIST for solid tumors, or Lugano for lymphoma, Up to 30 days after last dose of study drug
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.